

RISKeLearning

Nanotechnology – Applications and Implications for Superfund



SBRP/NIEHS

William Suk
Heather Henry
Claudia Thompson
Beth Anderson
Kathy Ahlmark
David Balshaw

September 12, 2007

Session 7:

“Nanoparticles: Human Toxicology and
Risk Assessment”

Kevin Dreher, US EPA

Agnes Kane and Robert Hurt, Brown
University

Stephen Roberts, University of Florida




EPA

Michael Gill
Jayne Michaud
Warren Layne
Marian Olsen
Charles Maurice

Nora Savage
Barbara Walton
Randall Wentzel
Mitch Lasat
Martha Otto

MDB

Maureen Avakian
Larry Whitson
Larry Reed




Pulmonary Effects of Nanoparticles: Insight Into Challenges Associated with Nanotechnology Health Risk Assessment

Kevin Dreher, Ph.D.
U.S. Environmental Protection Agency
Office of Research and Development
National Health and Environmental Effects Laboratory
Research Triangle Park, NC
dreher.kevin@epa.gov

NIEHS Nanotechnology Web Seminar:
Nanoparticle Health Effects
September 12, 2007


1



Pulmonary Effects of Nanoparticles

Presentation Outline

- ▶ Highlight Challenges in Nanoparticle/Nanotechnology Health Risk Assessment
- ▶ Pulmonary Toxicology of Nanomaterials:
 - Dosimetry, Fate, and Effects
 - Factors Regulating Toxicity
- ▶ Extra-Pulmonary Toxicity (Local vs. Systemic)
- ▶ Summary



Carbon Allotropy


1

K. Dreher, US EPA, ORD, NHEERL

2

Pulmonary Effects of Nanoparticles

Categories of Nanoparticles



<100nm; unique physicochemical properties due to size;
specific applications

1



K. Dreher, US EPA, ORD, NHEERL

3


Pulmonary Effects of Nanoparticles

Challenge: Diversity of Nanoparticles

Single and multi walled nanotubes




Fullerenes



Nanoshells




Metal oxides




Dendrimers



Quantum dots



Nanosomes



N. Walker, National Toxicology Program

1


K. Dreher, US EPA, ORD, NHEERL

4



Pulmonary Effects of Nanoparticles

Challenge: Complexity Within Nanoparticle Classes

Carbon Based Nanomaterials




SWCNT
&
MWCNT




Nanometals / Nanometal Oxides

nZVI



nTiO₂*



*, 2 production methods

** , doped (V; Nb)


nCeO₂ - five different production methods

Pulmonary Effects of Nanoparticles

*Challenge: Indirect Health Effects of Nanotechnology
(Production and Use of Nanomaterials)*



Remediation



Air Pollution Control/Energy



Interactions with Environmental Media (Air, Water, Soil)?

Transformation(s), and Potential Health Effects?

Diesel Exhaust "non-nano" Cerium Additive:

- ↑ >50% in each: benzene; 1,3-butadiene; acetaldehyde (Air Toxics*)
- ↓ 80% PAHs (Air Toxic)
- ↓ 8-20% NO_x (NAAQ*)
- ↑ 50-100% CO (NAAQ)
- ↑ Ambient Air Levels of Ce (Predicted)

*Changes in regulated air pollutants



1

K. Dreher, US EPA, ORD, NHEERL


6

Pulmonary Effects of Nanoparticles

*Challenge: Indirect Health Effects of Nanotechnology
(Production and Use of Nanomaterials)*



Remediation



Air Pollution Control/Energy




Interactions with Environmental Media (Air, Water, Soil)?

Transformation(s), and Potential Health Effects?

No Ozone

Ozone




1

K. Dreher, US EPA, ORD, NHEERL

Chen et al., *J. Phys. Chem.*, 110, 2006

Pulmonary Effects of Nanoparticles

Dosimetry: Differential Deposition of Nanoparticles




Oberdorster³, *EHP*, 2005; Oberdorster et al., *Inhal. Tox.*, 2004

1

K. Dreher, US EPA, ORD, NHEERL

Pulmonary Effects of Nanoparticles

Differential Clearance/Fate (Biokinetics) of Nanoparticles



9

Oberdorster et al., *EHP*, 113, 2005; Oberdorster et al., *Inhal. Tox.*, 16, 2004

K. Dreher, US EPA, ORD, NHEERL

Pulmonary Effects of Nanoparticles

Challenge: Translocation and Fate in Biological Systems
(Local & Systemic Toxicities)

Rats





Figure 2. Relative distribution of particles localized in the different lung compartments at 1 hr and 24 hr after inhalation. Volume densities (V_v) for lung tissue compartments from Burri et al. (1973), Pinkerton et al. (1992), and Tschanz et al. (1995, 2003).

Geiser et al., *EHP*, 113, 2005
-nTiO₂, 22nm CMD (4nm primary)
-Inhalation, 110 µg/m³, 1 h

Rats



Oberdorster et al., *Inhal. Tox.*, 2004
Oberdorster et al., *JTEH*, 2002


10

Pulmonary Effects of Nanoparticles

Challenge: Translocation and Fate in Biological Systems

Fate of nTiO₂ Following Oral Exposure

- ▶ Wang et al., *Tox. Lett.*, 168:176-185, 2007
- CD-1(ICR), 19gr, male and female mice
- oral gavage, 5 gr/kg BW
- 25 nm, 80 nm, 155 nm (fine) TiO₂
- 2 weeks post-exposure



*GI Uptake Distribution Only in Female Mice
(Host Susceptibility Factors)*

11

1

K. Dreher, US EPA, ORD, NHEERL

Pulmonary Effects of Nanoparticles

*Challenge: Health Effects/Toxicity of Nanoparticles
(Toxicity and Mechanism(s) of Injury Unique to "Nanoparticles"; Local vs. Systemic
Toxicities; Adequacy of Existing Toxicological Databases)*

SWCNT - Toxicity

► Warheit et al., *Tox. Sci.*, 77, 2004

- CrI:CD(SD) IGS BR, male rats
- Crude SWCNT (laser ablation)
- Comparative: quartz; graphite; carbonyl iron
- IT-instillation, 5 mg/kg BW
- 3 mon post-exposure

► Lam et al., *Tox. Sci.*, 77, 2004

- B6C3F, male mice
- Crude & Pure SWCNT (HiPCo; Arc Produced)
- SWCNT (Arch Generated)
- IT-instillation, 0.1, 0.5 mg/kg BW
- 3 mon post-exposure

► Shvedova et al., *Am. J. Physiol. Lung Cell Mol. Physiol.*, 289, 2005


- C57BL/6, female mice
- Pure SWCNT (HiPCo)
- Comparative: silica; nano carbon black
- PA; 0, 10, 20, 40 µg/mouse
- Up to 60 days post-exposure

Pulmonary Effects of Nanoparticles

Challenge: Health Effects/Toxicity of Nanoparticles

SWCNT - Results

- Pro-inflammatory and fibrogenic response; increase in cytokines and granuloma formation
- Alteration in pulmonary function
- Decreased pulmonary bacterial clearance
- Comparative toxicological assessment using equivalent mass exposure:
SWCNT = Quartz >> nano Carbon Black > Graphite
 - MSDS sheet reference graphite for health hazard specifications
 - Toxicity unique to "nanoness" (?)
- Pristine (raw) more toxic than purified
 - Hazard identification - role of metals and oxidative stress (surface reactivity)



13

1

K. Dreher, US EPA, ORD, NHEERL

Pulmonary Effects of Nanoparticles

Challenge: Health Effects/Toxicity of Nanoparticles

SWCNT Toxicity Dependent on Production Method

TABLE 2						
Incidence of Pulmonary Lesions in Mice 90 Days After Intratracheal Instillation with Nanotubes*						
Dust dose (mg)	Type of lung lesion	Carbon black	Quartz	(HiPco)		(Arc)
				RNT	PNT	CNT
0.1	Inflammation	0	1	3	2	0
0.1	Granulomas	0	0	5	2	0
0.5	Inflammation	0	4	3	5	0
0.5	Granulomas	0	0	5	5	5**

Lam et al. *TOX SCI*, 2004

14

Pulmonary Effects of Nanoparticles

Comparative In Vitro Pulmonary Toxicity: Engineered vs. Manufactured vs. Environmental Particles*

Particle	EC ₅₀ (μg/ml)					% of Cells with CNT
	Cell Number	WST-1	MTT	LDH	TBARS	
SWCNT-1**	65	50	17	-	-	74±9
SWCNT- 2	>100	>100	30	-	-	60±7
SWCNT- 3	85	>100	52	-	-	82±7
SWCNT- 4	18	>100	>100	-	-	77±4
ufCB		>200	>200	+	-	
NGF		>200	>200	+	-	
JDEP		45	60	+	++	
CFA		120	100	+	+/-	
ROFA		~8	15	+	+++	

* Human Airway Epithelial Cells

** >90% pure and production methods: 1) CVD; 2) Arc; 3) HiPco; 4) Laser

SWCNT Hierarchy: #4 (Laser) > #1 (CVD) > #3 (HiPco) > #2 (Arc)

Dreher et al., The Toxicologist, 96 (1), #1113, 2007

K. Dreher, US EPA, ORD, NHEERL

15

Comparative In Vitro Pulmonary* Toxicity: Engineered vs. Manufactured vs. Environmental Particles

SWCNT Hierarchy: #4 (Laser) > #1 (CVD) > #3 (HiPco) > #2 (Arc)

Dreher et al., The Toxicologist, 96 (1), #1113, 2007

Pulmonary Effects of Nanoparticles

Challenge: Health Effects/Toxicity of Nanoparticles

MWCNT - Toxicity

► *Muller et al., Toxicol. Appl. Pharmacol. 207, 2005*

- Crl:CD(SD), female rats
- Purified MWCNT (unground vs. ground)
- Unground MWCNT: 5.9 μ m; 5nm ID; 10nm OD
- Ground MWCNT: 0.7 μ m; 5nm ID; 11nm OD
- Comparative: nano-carbon black; asbestos (chrysotile A)
- IT-instillation, 0.5, 2, 5 mg/rat
- 3, 15, 60 days post-exposure

► *Carrero-Sanchez et al., Nano Letters, 6, 2006*


- CD1 male mice
- Purified MWCNT
- CNx-MWCNT
- oral, nasal, IT, IP, 1, 2.5, 5 mg/kg BW
- Up to 30 days post-exposure

Pulmonary Effects of Nanoparticles

Challenge: Health Effects/Toxicity of Nanoparticles

MWCNT -Results


- Pro-inflammatory and fibrogenic with granuloma formation by ground, unground, and surface unmodified MWCNT
 - more granulomas/inflammation with ground MWCNT
- Greater clearance of ground vs. unground
- MWCNT more toxic than CNx-MWCNT
 - Hazard identification - surface reactivity
 - Toxicity unique to "nanoness" (?)
- Comparative Toxicity:
 - Asbestos $\geq$ Ground > Unground > nanoCB



17

1

K. Dreher, US EPA, ORD, NHEERL




Pulmonary Effects of Nanoparticles

Challenge: CNT Hazard Identification (Multi-Factorial)

Preliminary studies indicate pulmonary toxicity of SWCNTs/MWCNTs is regulated by production method, length, purity (catalysts; substrates), and surface modifications

Do SWCNTs/MWCNTs conform to a fiber paradigm?


- aspect ratio (diameter, length)
- surface reactivity/chemistry



Pulmonary Effects of Nanoparticles

Challenge: Hazard Identification: More Than Size/Surface Area

Pulmonary Inflammation



Sal	nCo	nCB	nTi	nNi
Dia. nm:	20	14	20	20
SA:	37	254	50	36

Free Radical Activity: +++ + +/- ++

1

Dick et al., *Inhal. Toxicol.* 15, 2003

K. Dreher, US EPA, ORD, NHEERL

19

Pulmonary Effects of Nanoparticles

Challenge: Hazard Identification: More Than Size/Surface Area

Nanoscale SiO₂: "Toxicity Dependent on Surface Characteristics"

Sample	Average Size (nm)	Size Range (nm)	Surface Area (m ² /g)	Crystallinity	ICP-AES (% Fe content)
nano quartz I	50	30-65	31.4	α-quartz	0.080%
nano quartz II	12	10-20	90.5	α-quartz	0.034%
fine quartz	300	100-500	4.2	α-quartz	0.011%
Min-U-Sil	534	300-700	5.1	α-quartz	0.042%

Endpoint	Min-U-Sil	Nano quartz I	Nano quartz II	Fine quartz
Particle size	++++	++	+	+++
Surface area	+	+++	++++	++
Fe content	++	+++	++	+
Crystallinity	++++	++++	++++	++++
Radical content	++++	++	+++	-
Hemolytic potential	+++	+	+++	++
Lung inflammation	+++	++	+++	++
Cytotoxicity	+++	++	+++	+
Airway BrdU	++	NA	++	+
Lung paren. BrdU	++	NA	++	+
Histopathology	+++	NA	++++	++

n quartz II = min u sil quartz > fine > n quartz I > carbonyl iron

1

K. Dreher, US EPA, ORD, NHEERL

Warheit et al., *Toxicol. Sci.*, 95, 2007



20

Pulmonary Effects of Nanoparticles

Challenge: Systemic Effects of Pulmonary Deposited Nanoparticles

SWCNT - Vascular Toxicity

- ▶ Li et al., *EHP*, 115, 2007
 - ApoE^{-/-} transgenic, male mice
 - Purified SWCNT (HiPco)
 - Oropharyngeal aspiration, 20 μ g/mouse, once every 2 weeks for 8 weeks
 - 8 weeks post-exposure
- ▶ Results:
 - Inc. plaque size (aorta and BCA) and cellular inflammation in BCA
 - No evidence of systemic inflammation
 - Inc. in aortic mitoDNA damage
 - Evidence of aortic mitochondrial oxidative stress




K. Dreher, US EPA, ORD, NHEERL

Pulmonary Effects of Nanoparticles

Challenge: Systemic Effects of Pulmonary Deposited Nanoparticles

No Acute Pulmonary
Inflammation

Dose Dependent Alterations in
Vascular Function



Nurkiewicz, et al. 2007, American J. Physiology, Submitted.

1

K. Dreher, US EPA, ORD, NHEERL


22


Pulmonary Effects of Nanoparticles

Challenge: Systemic Toxicities Following Oral Exposure to Nanoparticles

- ▶ Wang et al., *Tox. Lett.*, 168:176-185, 2007
 - CD-1(ICR), 19gr, male and female mice
 - oral gavage, 5 gr/kg BW
 - 25nm, 80nm, 155nm (fine) TiO₂
 - 2 weeks post-exposure
- ▶ Results:
 - GI uptake and systemic distribution only in female mice (susceptibility)
 - local inflammation in stomach
 - hepatic toxicity (pathology; inc. serum ALT/AST levels)
 - nephrotoxicity (pathology; inc. serum BUN level)
 - myocardial toxicity (inc. serum LDH and HBDH levels)

Fate of nTiO₂ Following Oral Exposure






Pulmonary Effects of Nanoparticles: Insight Into Challenges Associated with Nanotechnology Health Risk Assessment

Summary

- ▶ **Challenges in Nanoparticle/Nanotechnology Health Risk Assessment**
 - Diversity of nanoparticles and their applications
 - Health effects of nanoparticles, their production/applications, and environmental interactions (comprehensive strategy)
 - Nanoparticle deposition, fate, detection in biological systems
- ▶ **Pulmonary Toxicity of Nanoparticles:**
 - Size influences deposition and fate (translocation of nanoparticles)
 - Some evidence that toxicity may be unique to "nanoness"
 - Hazard identification is multi-factorial ("more than just size/surface area")
 - Mechanism of injury: oxidative stress (but how; are there other mechanisms)
 - Local vs. systemic toxicities (which are most critical)
 - Host susceptibility factors contribute



1

24

K. Dreher, US EPA, ORD, NHEERL

Nanoparticles: Health Effects


Agnes B. Kane, M.D., Ph.D

Department of Pathology and Laboratory Medicine

Robert H. Hurt, Ph.D.

Division of Engineering


Brown University, Providence, Rhode Island




Nanotechnology has Given Rise to an Amazing Variety of New Materials

Equi-axed forms (nanoparticles)

- fullerenes (carbon)
- metallic nanoparticles (e.g. Au, Fe, Ni)
- nanophase ceramics and polymers
- dendrimers
- quantum dots (semiconductor NPs)



Fe/silica core/shell; Sun, Nurmikko



Carbon nanoparticles

One-dimensional (fibrous) forms

- carbon nanotubes
- nanofibers (carbon, polymer, ceramic)
- nanowires (usually metals)
- nanorods (any chemistry, modest L/D)



Single-wall nanotube bundle,
Thess 1996



Two-dimensional (lamellar) forms

Nanoplatelet graphite, clay,
graphene


Nanostructured surfaces

Nanostructured solids

Nanofiber-cell
interaction





Conventional Grain Size



Nanoscale Grain Size

From T.J. Webster

Many Nanomaterial Samples are Complex Mixtures



Ideal nanotube
structure
(J. Xu et al.)


Actual nanotube
structure
(commercial, as-produced)



BROWN

Basic nanomaterial properties relevant to toxicity


- Size
 - small: elevated surface area and surface activity
- Shape
 - fibrous geometry impedes macrophage clearance
- Biopersistence
- Surface chemistry
 - hydrophobicity
 - surface charge
 - redox activity
- Release of chemical toxicants



Surface Reactivity of Nanoparticles
Nel et al. Science 311: 622-627, 2006






28

Carbon nanotubes can be redox active through release of bioavailable iron



Cytotoxicity of Fullerenes Depends on Surface State

Sayes et al.
NANO LETTERS
2004 Vol. 4, No. 10
1881-1887


Fullerene Species	Structure	Live Stain	Dead Stain
C ₆₀			
C ₃			
$\text{Na}^+_{2-3} [\text{C}_{60}\text{O}_{7-9}(\text{OH})_{12-15}]^{2-3-}$			
C ₆₀ (OH) ₂₄			

Carbon material hydrophobicity varies with synthesis, processing and functionalization
 1 "Controlling Water Contact Angle on Carbon from 5 to 167 Degrees" [Yan et al., 2006]


30

Possible Mechanisms of Fullerene Toxicity

based on Sayes et al., 2004, Oberdorster, 2004




Some important nanomaterials contain known chemical toxicants imbedded in core/shell structures




QD-LED Display

Quantum dot fluorescence, example LED display application, and core/shell structure



BROWN

Imbedded metal structures in carbon nanotubes




32



Catalyst Residues in Carbon Nanotubes

- Catalytic growth methods:
 - now dominant for synthesis of multiwall nanotubes (esp. large scale)
 - only route for single-wall nanotube synthesis
- Most common elements in CNT catalyst formulations are Fe, Ni, Y, Co, Mo
- Ultrafine metals pose documented inhalation health risks depending on form, exposure route, dose
- Do metals contribute to CNT toxicity?
How can we assay for and manage CNT metals effects?



Bioavailability?
(the key issue)



BROWN

Iron Bioavailability and Redox Activity of Diverse Carbon Nanotube Samples

From Guo et al.,
Chemistry of Materials
2007




Fe mobilization

DNA
single-strand
breaks

34

Molecular mechanisms of Ni toxicity






BROWN

35

Environmental and Processing Stresses Affect Metal Bioavailability and Toxicity


[Liu et al, Advanced Materials, in press]



BROWN

36

Toward Carbon Nanotube Detoxification



Toxicology of Engineered Nanomaterials

[Oberdörster et al., Environ. Health Persp. 113:823-839, 2005]

EXPOSURE → DOSE → RESPONSE

Source? *air*
water
food
diagnostic or
medical device

Dose metric? *mass*
number
surface area

portal of entry?
systemic
distribution?
remote effects?

Route of uptake? *inhalation*
ingestion
skin
injection
implantation

which organ?
which cell?
persistence at this
site?

desirable effects?
diagnostic
therapeutic

toxicity?
oxidative stress
immune function
acute vs. chronic


38

Are Nanomaterials the Next Asbestos Fibers?

History of Asbestos-Related Diseases

Becklake, Am. Rev. Resp. Dis. 114:187-227,1976

Disease	Suspected	Established Causal Association
Asbestosis	1900	1930
Lung Cancer	1930	1955
Mesothelioma	1940	1965
Cancer of Larynx	1955	2006
Nanodiseases	2001	????




Properties of Fibers Relevant for Biologic Activity



chrysotile asbestos

Fiber dimensions
Chemical composition
Durability
Surface reactivity




carbon nanofibers

Catalyst Precursors for Carbon Nanotube Production

Moisala et al., 2003

Iron sulfate hydrate
Iron ammonium sulfate
Iron, nickel, or cobalt nitrate
Iron chloride
Iron oxides




Lin Guo, Engineering graduate student



Asbestos Fibers Generate ROS at the Solid-Liquid Interface

Ghio et al. *Toxicol. Pathol.* 32:643-649, 2004




- Iron is essential for all biological organisms
- Iron is tightly bound to extracellular proteins (transferrin, lactoferrin) or to intracellular proteins (enzymes, ferritin)
- Asbestos fibers contain redox active iron linked with toxicity
- *Can redox-active iron be mobilized from carbon nanotubes?*




BROWN

41





Frustrated phagocytosis of an asbestos fiber by a macrophage



Induction of cell death (apoptosis)




BROWN

42



Lung Toxicity of Multiwall Carbon Nanotubes

Muller et al. Toxicol. Appl. Pharmacol. 207: 221-231, 2005



**“Supramolecular”
carbon nanoparticles
are taken up by
mesothelial cells
and are non-cytotoxic**



(Brown work, Yan et al., 2006)



Outward facing graphene
layers provide active sites
for functionalization





BROWN




44

- Penetration of nanoparticles into solid tumor masses



Systemic Distribution of Nanoparticles

Oberdörster et al., *Environ. Health Perspect.* 113: 823-839, 2005



46

POTENTIAL CHRONIC TOXICITY OF NANOMATERIALS

NEL ET AL. SCIENCE 311: 622-627, 2006

TISSUE TARGET	DISEASE
Macrophages and inflammatory cells	granulomas chronic inflammation fibrosis or scarring
Lungs	cancer, mesothelioma
Blood vessels	stroke, heart attack
Immune system	autoimmune disease leukemia, lymphoma
Nervous system, brain	heart arrhythmia brain injury



BROWN

Occupational Carcinogens




Agent	Industry	Target Site
Arsenic	Glass, metal, pesticide	Lung, Skin
Asbestos	Construction	Lung, Pleura, Larynx
Benzene	Chemical	Leukemia
Beryllium	Aerospace	Lung
Cadmium	Dyes, batteries	Lung, Prostate, Kidney
Chromium (VI)	Metal plating, welding	Lung, Nasal Sinus
Nickel	Metallurgy, alloys, catalyst	Lung Nasal Sinus
Crystalline silica	Mining, glass, pottery	Lung
Sulphuric acid mists	Metallurgy	Larynx

P. Boffetta, Epidemiology of environmental and occupational cancer, Oncogene 23: 6392-6403, 2004.







Toxicity of NiCl_2 Using Human Lung Epithelial Cells In Vitro

Syto-10/Ethidium Homodimer
Viability Assay – 48 hours (100x)






Phase Contrast Microscopy –
48 hours (100x)




Newport Green DCF



Newport Green Fluorescence –
48 hours (200x)




Toxicity of Metallic Nickel Nanoparticles



Syto-10/Ethidium Homodimer
Viability Assay
- 72 hours (100x)



Newport Green fluorescence
- 72 hours- (200x)



1

50


The Opportunity

Most nanomaterials are:

- fabricated, not natural
- developmental, not commercial

Fabrication/purification processes greatly affect key toxicity variables:

- size, shape, surface chemistry
- metals content and location



Ultimate Goal: Understand material structure / toxicity relationships to guide development of “green” nanomaterials

51



Acknowledgements

Financial support for nanotoxicology work

- SBRP grant at Brown (NIEHS P42 ES013660)
- US EPA (STAR Grant RD83171901)
- NSF NIRT grant (DMI-050661)

The Hurt Lab

Indrek Kulaots, Ph.D.
Lin Guo
Xinyuan Liu
Love Sarin
Daniel Morris
Bevan Weissman
Aihui Yan

The Kane Lab

52

Charles A. Vaslet, Ph.D.
Kevin McNeil
Norma Messier
Nathan Miselis
Jodie Pietruska
Vanessa Sanchez
Ashley Smith



BROWN

Risk Assessment of Nanomaterials

Steve Roberts

***Center for Environmental & Human Toxicology
University of Florida***



53



Overview of Issues

The premise for nanotechnology is that nanoscale materials have new, beneficial properties:

- unique physical-chemical and material properties
- new biological properties that will be useful for diagnostics and therapeutics

If biological properties change as materials move to nanoscale, then maybe our knowledge of the toxicological properties of these materials no longer applies.

- kinds of effects produced
- doses at which effects occur



Nanotoxicology at the University of Florida



Concerns for Risks from Nanotechnology

Examples of calls to slow or halt nanotechnology development

“Until more is known about environmental impacts of nanoparticles and nanotubes, we recommend that the release of manufactured nanoparticles and nanotubes into the environment be avoided as far as possible.”

Nanoscience and Nanotechnologies: Opportunities and Uncertainties, 2004

“At this stage, we know practically nothing about the potential cumulative impact of human-made nano-scale particles on human health and the environment. Given the concerns raised over nanoparticle contamination in living organisms, ETC Group proposes that governments declare an immediate moratorium on commercial production of new nanomaterials and launch a transparent global process for evaluating the socio-economic, health and environmental implications of the technology.”

The Big Down, AtomTech: Technologies Converging at the Nano-scale, 2003

Filling the Void



from Friends of the Earth, 2004

Sense of risk is conveyed not by affirmative evidence of hazard, but rather by the absence of evidence for safety.

Federal Funding for EHS Research

Table 6 Budget for Environmental, Health, and Safety R&D, 2006–2008 (dollars in millions)			
	2006 Actual	2007 Estimate	2008 Request
NSF	21.0	25.7	28.8
DOD	1.0	1.0	1.0
DOE	0.5	0.0	3.0
DHHS (NIH)	5.2	5.4	5.7
DOC (NIST)	2.4	2.8	5.8
NASA	0.0	0.0	0.0
EPA	3.7	7.9	9.6
USDA (CSREES)	0.1	0.1	0.1
DHHS (NIOSH)	3.8	4.9	4.6
USDA (FS)	0.0	0.0	0.0
DHS	0.0	0.0	0.0
DOJ	0.0	0.0	0.0
DOT (FHWA)	0.0	0.0	0.0
TOTAL	37.7	47.8	58.6

From Supplement to the President's FY 2008 Budget, National Nanotechnology Initiative

Risk Assessment Steps

Hazard Identification

- Determination whether a particular substance is causally linked to particular health effects.

Exposure Assessment

- Determination of the extent of exposure before or after application of regulatory controls.

Dose-response assessment

- Determination of the relationship between the magnitude of exposure and the probability of occurrence of the health effects in question.

Risk Characterization

- Description of the nature and often the magnitude of human risk, including attendant uncertainty.

Adapted from *Risk Assessment in the Federal Government: Managing the Process*, NRC 1983

Challenges in Studying Toxicity

Time to complete the studies - A battery of studies to satisfy regulatory concerns about safety can take years to complete.

Prioritizing nanomaterials for study - Field is advancing quickly; nanomaterials of interest are rapidly replaced by newer nanomaterials.

Consistency of materials - Manufacturing techniques for many nanomaterials are still being worked out; poor quality control.

Relevant exposures - Almost no studies available showing actual exposure conditions.

Amount of materials required for testing - New nanomaterials are often available only in small quantities and are very expensive.

More Challenges ...

Characterizing the test material - Both chemical and physical properties of nanoscale materials can change with time, handling, and in biological environments.

Characterizing the dose - There is uncertainty as to whether doses should be expressed in terms of mass, surface area, or particle concentration.

Measurement of nanomaterials in tissues - Detection and quantification of nanostructures in tissues is difficult. High resolution microscopy (e.g., transmission electron microscopy) is often required.

Hazard Identification

What kinds of health effects do nanoscale materials produce?

- Are the effects the same as produced by the same material in conventional scale?


MATERIAL SAFETY DATA SHEET			
OSHA - Meets 29 CFR 1910.1200 Standards		HMIS HAZARD RATINGS	
	HEALTH	1	0 = INSIGNIFICANT
	FLAMMABILITY	4	1 = SLIGHT
	REACTIVITY	2	2 = MODERATE
TRANSPORTATION INFORMATION PROPER SHIPPING NAME: Aluminum powder, uncoated HAZARD CLASS / PKG GRP: 4.3 / III IDENTIFICATION NUMBER: UN 1395 REF: 49 CFR 173.151, 213, 244 LABEL: Dangerous When Wet			
HEALTH HAZARDS (ACUTE AND CHRONIC): The toxicological properties and health hazards associated with this material as a very fine powder have not been investigated. However, it is assumed this product presents the same health hazards as the product in standard powder form. Use appropriate procedures and protective equipment to prevent opportunities for direct contact with the skin or eyes and to prevent inhalation.			
CARCINOGENICITY	NTP?	No	OSHA REGULATED? No
MEDICAL CONDITIONS GENERALLY AGGRAVATED BY EXPOSURE: Preexisting skin, eye, or respiratory disorders may become aggravated through prolonged exposure.			

Hazard ID Points


Changes in properties in moving to nanoscale:

- 1) could lead to fundamentally different biological effects and/or profound changes in absorption or distribution of the material (compared with conventional scale).
- 2) can be different for different materials.
- 3) can result from changes in size, shape, and/or surface characteristics.
 - This greatly complicates hazard identification, particularly since the factors influencing toxicity for each material are, at this point, largely unknown.
 - Adequate characterization of materials used in toxicity tests is extremely important.
 - Characterization should include the material as administered, not just as received.

Size Matters - But what size is it?



Median Diameter (by Volume)	14.4 microns
Median Diameter (by Number)	151 nm
Specific Surface Area	25.7m ² /g 80 nm (equivalent)



Nanotoxicology at the University of Florida


63



Surface Properties

For aluminum particles, cytotoxicity appears to be determined by the oxide coat.


- Aluminum oxide passivates the surface, decreasing reactivity and toxicity.
- The stability of the aluminum oxide coat is a function of particle size; smaller particles have less stable coats and are more cytotoxic.



- The oxide coat varies depending upon length of exposure to air or water.
- Results can vary depending not only upon size, but also “aging” of material.

Exposure Assessment

Potential exposure scenarios should be considered in the context of a life cycle analysis



From Tsuji et al., Tox. Sci. (2006), v. 89(1), pp 42-50.

Exposure Assessment Issues

Nanoscale materials pose special issues for each of the three primary routes of exposure:


- inhalation
- dermal absorption
- ingestion

Toxicity studies should be conducted using the same nanomaterial forms that exist under actual exposure conditions

- for example, extent of aggregation, surface properties
- understanding of environmental fate is critical

Altered Properties During Exposure

Comparison of size distribution of aluminum nanoparticles in water versus culture media with 5% fetal bovine albumin (FBS)



Courtesy of M. Palazuelos, UF


Detection




Quantum dots in GI tract of *Daphnia*
Courtesy of J. Griffith, UF

Detection of structurally-intact nanomaterials can be very challenging, particularly in tissues.

The most straightforward way to observe and measure nanoparticles in tissues is with microscopy, but microscopic techniques are technically demanding.



Colloidal gold on
mouse skin
Courtesy of S.
Wasdo, UF




Fluorescence tagged
SWCNTs
Courtesy of R. Mercer,
NIOSH



Nanotoxicology at the University of Florida

Dose-Response Assessment

What is the correct dose metric?



From Oberdoster et al., EHP (2005), v. 113(7), pp. 823-839

Recent Initiatives

Prioritization of Environmental, Health, and Safety Research Needs for Engineered Nanoscale Materials

- Nanotechnology Environmental and Health Implications Working Group, National Science and Technology Council
- Available on www.nano.gov; deadline for public comments is 09/17/07

Concept Paper for the Nanoscale Materials Stewardship Program under TSCA

- Available at epa.gov/oppt/nano/nmspfr.htm; deadline for public comment is 09/10/07

FDA Task Force Report on Nanotechnology, July 2007

- Available at www.fda.gov/nanotechnology/taskforce/report2007.html

Approaches to Safe Nanotechnology

- Available at www.cdc.gov/niosh/topics/nanotech/safenano/

QuickTime™ and a
TIFF (Uncompressed) decompressor
are needed to see this picture.

Conclusions

The existing risk assessment paradigm is suitable for evaluation of nanomaterials.

Data to support risk assessments is generally lacking.

Impediments to developing data include:

- Regulatory ambiguity on testing requirements
- Limited availability of funding for testing and research
- Technical challenges in conducting toxicity studies
- Data developed by industry is often unavailable

We currently have a risk assessment “void” being filled with speculation.

Federal agencies are moving forward to clarify the regulatory status of nanomaterials and sponsor environmental health and safety research.



Nanotoxicology at the University of Florida

Credits

Particle Engineering Center, UF

Maria Palazuelos

Kevin Powers


Brij Moudgil

Center for Environmental & Human Toxicology, UF


Scott Wasdo

Joe Griffitt

David Barber



aluminum flakes



Quartz Min-U-Sil



Nanotoxicology at the University of Florida

Thank You

After viewing the links to additional resources,
please complete our online feedback form.



Thank You

[Links to Additional Resources](#)

[Feedback Form](#)



Nanotoxicology at the University of Florida

73

